Physician profile
Ward B Rogers
NPI 1316961188
$3,541.65
in general payments reported to CMS, 2019-2025
25 companies · $440 in 2025
The $440 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $203 · 2021: $287 · 2022: $587 · 2023: $672 · 2024: $517 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625 · Education: $3.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.39 |
| Education | $3.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $590.71 | 2019-2025 | |
| Pfizer INC. | $499.38 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $411.71 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.91 | 2019-2024 | Jardiance |
| Amgen INC. | $248.14 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $226.20 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $172.38 | 2019-2022 | |
| Astellas Pharma US INC | $170.32 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $126.79 | 2019-2025 | Eliquis |
| Boston Scientific Corporation | $104.96 | 2019-2024 | Watchman Flx |
| Novo Nordisk INC | $95.34 | 2024-2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $85.68 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $78.95 | 2023-2024 | |
| Esperion Therapeutics, INC. | $47.60 | 2021-2024 | Nexletol |
| Edwards Lifesciences Corporation | $43.72 | 2025 | Sapien 3 Ultra Resilia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $39.75 | 2023-2024 | |
| Amarin Pharma, INC. | $31.18 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $30.50 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.01 | 2019-2022 | |
| Irhythm Technologies, INC. | $25.20 | 2020-2021 | |
| Glaxosmithkline, LLC. | $18.70 | 2025 | Arexvy, Shingrix |
| Actelion Pharmaceuticals US, INC. | $17.34 | 2021 | |
| Abbott Laboratories | $16.75 | 2022 | |
| Kestra Medical Technology Services, INC. | $15.74 | 2024 | Assure Wcd |
| Baxter Healthcare | $13.69 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ward Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.